Praxis Precision Medicines (PRAX)
(Delayed Data from NSDQ)
$50.88 USD
+0.89 (1.78%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $50.89 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Praxis Precision Medicines, Inc. [PRAX]
Reports for Purchase
Showing records 1 - 20 ( 104 total )
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
All That JAZZ --- Thoughts on Suvecaltamide, PRAX/ Ulixacaltamide
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
Top 16 Takeaways From Our Coverage at the H.C. Wainwright Bioconnect Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
Ulixacaltimide Nears Readout, Epilepsy Portfolio Advances; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
Looking Ahead to Essential3 Data in 2H24 [1Q24 Highlights]
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
Takeaways from Our Call with Praxis Management; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
Lighting Things Up With PRAX-628, But We''re Waiting For P2b Data
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
Today''s Data Offers a Strong Early Signal of PRAX-628''s Blockbuster Potential; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
After a Productive 2023, 2024 Should Be a Banner Year for Praxis
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
PPR Update Comes Next (1Q24), As ET Efforts Progress
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
Preliminary PPR Results For 15mg Cohort Provide a Win; What We''re Looking for Next
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
Adding The Financing; Removes Cash Runway Overhang But Sticking With Sidelines
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
PRAX-628 Shows a Signal in PPR Study; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
Praxis Monetizes Ulixa China Opportunity; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
Live From AES: PRAX-222 Continues To Show Compelling Results
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D